^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Mucosal Melanoma

    Related cancers:
    2d
    CD8/CD4 ratio, CD56, and PD-L1 as prognostic markers in sinonasal mucosal melanoma. (PubMed, Int J Clin Oncol)
    Immune markers, particularly the CD8/CD4 ratio and CD56-positive lymphocytes, were significantly associated with survival outcomes independent of traditional histopathologic factors. Incorporating immune profiling into risk stratification may improve prognostication and guide the development of immune-targeted strategies in SNMM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
    |
    PD-L1 expression
    3d
    A Single-Arm, Phase II Clinical Study of QL1706 in Combination with Lenvatinib for the Neoadjuvant Treatment of Resectable Extremity and Mucosal Melanoma (ChiCTR2500112240)
    P2, N=20, Recruiting, Fujian Provincial Tumor Hospital; Fujian Provincial Tumor Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • temozolomide • Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    3d
    QL1706 Single-Agent Phase II Clinical Study for Neoadjuvant Treatment of Resectable Acral and Mucosal Melanoma (ChiCTR2500112379)
    P2, N=29, Recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • temozolomide • Qibeian (iparomlimab/tuvonralimab)
    5d
    Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma (clinicaltrials.gov)
    P2, N=75, Recruiting, M.D. Anderson Cancer Center | Phase classification: P=N/A --> P2
    Phase classification
    6d
    Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    7d
    BNT326-01: A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors (clinicaltrials.gov)
    P1/2, N=980, Recruiting, BioNTech SE | N=550 --> 980 | Trial completion date: Feb 2030 --> Oct 2029 | Trial primary completion date: May 2028 --> Feb 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • ALK rearrangement • PD-L1 expression + HER-2 overexpression • HER-2 negative + HR negative
    |
    itraconazole • pumitamig (BNT327)
    12d
    Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis. (PubMed, J Immunother Cancer)
    ca-4F12-E6 exhibited durable antitumor activity with manageable safety profile in dogs with OMM. Baseline systemic inflammatory markers and MSI status may serve as predictive biomarkers for clinical outcomes. The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    12d
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=99, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    12d
    Exploration of Therapeutic Targets Using CDK4 Inhibitors for Head and Neck Mucosal Melanoma. (PubMed, Otolaryngol Head Neck Surg)
    Abemaciclib and palbociclib may suppress MM cell proliferation. The CDK4 signaling pathway is a potential target for molecular-targeted therapies in MM.
    Journal
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)
    13d
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    14d
    IMMUQ: Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Recruiting --> Active, not recruiting | Trial completion date: May 2028 --> Jan 2029 | Trial primary completion date: May 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    14d
    A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II) (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    temozolomide • Lenvima (lenvatinib) • Puyouheng (pucotenlimab)